A Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of VIR-2218 Alone or in Combination With Pegylated Interferon Alpha-2a
| Registry | NCT04412863 |
|---|
| Status | Completed |
|---|
| Phase | Phase 2 |
|---|
| Study type | Interventional; non randomized, parallel, masking: none, treatment |
|---|
| Enrollment | 84 (Actual) |
|---|
| Sponsor | Vir Biotechnology, Inc. (Industry); collaborators: Alnylam Pharmaceuticals |
|---|
| Conditions | Chronic Hepatitis B |
|---|
| Interventions | VIR-2218, pegylated interferon-alfa 2a (Drug) |
|---|
| Dates | start 2020-07-03, primary completion 2024-03-25, completion 2024-03-25, first posted 2020-06-02, last updated 2026-04-16 |
|---|
| Locations | 22 sites in Australia, Hong Kong, Malaysia, New Zealand, South Korea, Thailand |
|---|
Related Papers Related Patents Related Grants Related Experts
All trials for Chronic Hepatitis B All trials of VIR-2218 All trials of pegylated interferon-alfa 2a
-Summary
This is a phase 2 study in which subjects with chronic hepatitis B virus (HBV) infection will receive VIR-2218 alone or in combination with pegylated interferon alfa-2a and will be assessed for safety, tolerability, pharmacokinetics, and antiviral activity.
Expand all sections · Collapse all
+Arms and interventions
| Arm | Type | Interventions | Description |
|---|
| Cohort 1d | Experimental | Drug: VIR-2218 | VIR-2218 given by subcutaneous injection |
| Cohort 2d | Experimental | Drug: VIR-2218; Drug: pegylated interferon-alfa 2a | VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection |
| Cohort 3d | Experimental | Drug: VIR-2218; Drug: pegylated interferon-alfa 2a | VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection |
| Cohort 1e | Experimental | Drug: VIR-2218 | VIR-2218 given by subcutaneous injection |
| Cohort 2e | Experimental | Drug: VIR-2218; Drug: pegylated interferon-alfa 2a | VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection |
| Cohort 3e | Experimental | Drug: VIR-2218; Drug: pegylated interferon-alfa 2a | VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection |
| Cohort 1f | Experimental | Drug: VIR-2218; Drug: pegylated interferon-alfa 2a | VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection |
| Cohort 2f | Experimental | Drug: VIR-2218; Drug: pegylated interferon-alfa 2a | VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection |
| Cohort 3f | Experimental | Drug: VIR-2218; Drug: pegylated interferon-alfa 2a | VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection |
- VIR-2218 (Drug), also known as Elebsiran: VIR-2218 given by subcutaneous injection
- pegylated interferon-alfa 2a (Drug), also known as pegylated interferon alpha-2a, PEG-IFNα: pegylated interferon-alfa 2a given by subcutaneous injection
+Outcome measures
Primary outcomes
- Number of Subjects With Adverse Events as Assessed by CTCAE v5.0 [Up to 148 Weeks]
- Number of Subjects With Abnormalities in Vital Signs, Electrocardiogram (ECG), and Clinically Significant Laboratory Findings [Up to 148 Weeks]
Secondary outcomes
- Mean Maximum Reduction of Serum HBsAg at Any Timepoint [Up to 148 Weeks]
- Proportion of Subjects With Serum HBsAg Loss (Undetectable HBsAg) at Any Timepoint [Up to 148 Weeks]
- Proportion of Subjects With Sustained Serum HBsAg Loss (Undetectable HBsAg) for Greater Than 6 Months [Up to 148 Weeks]
- Proportion of Subjects With Anti-HBs Seroconversion at Any Timepoint [Up to 148 Weeks]: Anti-HBs seroconversion is defined as Anti-HBs quantitative value changed from baseline <LLOQ (5 mIU/mL) to post-baseline>=LLOQ.
- For HBeAg-positive Patients: Proportion of Subjects With HBeAg Loss (Undetectable HBeAg) and/or Anti-HBe Seroconversion at Any Timepoint [Up to 148 weeks]
+Eligibility
Sex: All, ages: 18 Years to 65 Years
Inclusion Criteria:
* Male or female of ages 18 - 65
* Chronic HBV infection for >/= 6 months
Exclusion Criteria:
* Any clinically significant chronic or acute medical condition that makes the volunteer unsuitable for participation
* Significant fibrosis or cirrhosis
* History or evidence of drug or alcohol abuse
* History of intolerance to SC injection
* History of chronic liver disease from any cause other than chronic HBV infection
* History of hepatic decompensation
* Any prior receipt of an interferon product
+Posted results
Participant flow
| Milestone | Cohort 1d: VIR-2218 200 mg Q4W x 6 on NRTI | Cohort 2d: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 12 Starting at Week 12 on NRTI | Cohort 3d: VIR-2218 200 mg Q4W x 3 + PEG-IFNα 180 µg QW x 12 on NRTI | Cohort 1f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 24 on NRTI | Cohort 2f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x ≤ 48 on NRTI | Cohort 3f: VIR-2218 200 mg Q4W x ≤13 + PEG-IFNα 180 µg QW x ≤ 44 on NRTI |
|---|
| Started | 15 | 15 | 5 | 18 | 18 | 13 |
| Completed | 9 | 15 | 5 | 17 | 16 | 13 |
| Not completed | 6 | 0 | 0 | 1 | 2 | 0 |
Outcome results
- Number of Subjects With Adverse Events as Assessed by CTCAE v5.0 (Primary), Count of participants, Participants: Cohort 1d: VIR-2218 200 mg Q4W x 6 on NRTI 9; Cohort 2d: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 12 Starting at Week 12 on NRTI 13; Cohort 3d: VIR-2218 200 mg Q4W x 3 + PEG-IFNα 180 µg QW x 12 on NRTI 3; Cohort 1f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 24 on NRTI 16; Cohort 2f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x ≤ 48 on NRTI 17; Cohort 3f: VIR-2218 200 mg Q4W x ≤13 + PEG-IFNα 180 µg QW x ≤ 44 on NRTI 13
- Number of Subjects With Abnormalities in Vital Signs, Electrocardiogram (ECG), and Clinically Significant Laboratory Findings (Primary), Count of participants, Participants: Cohort 1d: VIR-2218 200 mg Q4W x 6 on NRTI 2; Cohort 2d: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 12 Starting at Week 12 on NRTI 12; Cohort 3d: VIR-2218 200 mg Q4W x 3 + PEG-IFNα 180 µg QW x 12 on NRTI 2; Cohort 1f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 24 on NRTI 12; Cohort 2f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x ≤ 48 on NRTI 14; Cohort 3f: VIR-2218 200 mg Q4W x ≤13 + PEG-IFNα 180 µg QW x ≤ 44 on NRTI 9
- Mean Maximum Reduction of Serum HBsAg at Any Timepoint (Secondary), Mean, Log 10 IU/mL: Cohort 1d: VIR-2218 200 mg Q4W x 6 on NRTI -1.96 +/- 0.29; Cohort 2d: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 12 Starting at Week 12 on NRTI -2.15 +/- 0.61; Cohort 3d: VIR-2218 200 mg Q4W x 3 + PEG-IFNα 180 µg QW x 12 on NRTI -1.73 +/- 0.37; Cohort 1f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 24 on NRTI -2.52 +/- 0.82; Cohort 2f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x ≤ 48 on NRTI -2.48 +/- 1.41; Cohort 3f: VIR-2218 200 mg Q4W x ≤13 + PEG-IFNα 180 µg QW x ≤ 44 on NRTI -2.99 +/- 1.32
- Proportion of Subjects With Serum HBsAg Loss (Undetectable HBsAg) at Any Timepoint (Secondary), Count of participants, Participants: Cohort 1d: VIR-2218 200 mg Q4W x 6 on NRTI 0; Cohort 2d: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 12 Starting at Week 12 on NRTI 1; Cohort 3d: VIR-2218 200 mg Q4W x 3 + PEG-IFNα 180 µg QW x 12 on NRTI 0; Cohort 1f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 24 on NRTI 2; Cohort 2f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x ≤ 48 on NRTI 6; Cohort 3f: VIR-2218 200 mg Q4W x ≤13 + PEG-IFNα 180 µg QW x ≤ 44 on NRTI 4
- Proportion of Subjects With Sustained Serum HBsAg Loss (Undetectable HBsAg) for Greater Than 6 Months (Secondary), Count of participants, Participants: Cohort 1d: VIR-2218 200 mg Q4W x 6 on NRTI 0; Cohort 2d: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 12 Starting at Week 12 on NRTI 1; Cohort 3d: VIR-2218 200 mg Q4W x 3 + PEG-IFNα 180 µg QW x 12 on NRTI 0; Cohort 1f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 24 on NRTI 1; Cohort 2f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x ≤ 48 on NRTI 4; Cohort 3f: VIR-2218 200 mg Q4W x ≤13 + PEG-IFNα 180 µg QW x ≤ 44 on NRTI 2
- Proportion of Subjects With Anti-HBs Seroconversion at Any Timepoint (Secondary), Count of participants, Participants: Cohort 1d: VIR-2218 200 mg Q4W x 6 on NRTI 9; Cohort 2d: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 12 Starting at Week 12 on NRTI 8; Cohort 3d: VIR-2218 200 mg Q4W x 3 + PEG-IFNα 180 µg QW x 12 on NRTI 3; Cohort 1f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 24 on NRTI 7; Cohort 2f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x ≤ 48 on NRTI 4; Cohort 3f: VIR-2218 200 mg Q4W x ≤13 + PEG-IFNα 180 µg QW x ≤ 44 on NRTI 3
- For HBeAg-positive Patients: Proportion of Subjects With HBeAg Loss (Undetectable HBeAg) and/or Anti-HBe Seroconversion at Any Timepoint (Secondary), Count of participants, Participants: Cohort 1d: VIR-2218 200 mg Q4W x 6 on NRTI 1; Cohort 2d: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 12 Starting at Week 12 on NRTI 1; Cohort 3d: VIR-2218 200 mg Q4W x 3 + PEG-IFNα 180 µg QW x 12 on NRTI 0; Cohort 1f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 24 on NRTI 3; Cohort 2f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x ≤ 48 on NRTI 3; Cohort 3f: VIR-2218 200 mg Q4W x ≤13 + PEG-IFNα 180 µg QW x ≤ 44 on NRTI 1
Adverse events
Time frame: Treatment emergent serious adverse events were defined as AEs reported between Part 1D/2D: Day 1 through Week 27, Part 3D; Day 1 through Week 15, Part 1F: Day 1 through Week 27, Part 2F: Day 1 through Week 51, Part 3F: Day 1 through Week 52.
| Arm | Deaths | Serious adverse events | Other adverse events |
|---|
| Cohort 1d: VIR-2218 200 mg Q4W x 6 on NRTI | 0/15 (0.0%) | 0/15 (0.0%) | 9/15 (60.0%) |
| Cohort 2d: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 12 Starting at Week 12 on NRTI | 0/15 (0.0%) | 0/15 (0.0%) | 13/15 (86.7%) |
| Cohort 3d: VIR-2218 200 mg Q4W x 3 + PEG-IFNα 180 µg QW x 12 on NRTI | 0/5 (0.0%) | 0/5 (0.0%) | 3/5 (60.0%) |
| Cohort 1f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 24 on NRTI | 0/18 (0.0%) | 1/18 (5.6%) | 16/18 (88.9%) |
| Cohort 2f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x ≤ 48 on NRTI | 0/18 (0.0%) | 1/18 (5.6%) | 17/18 (94.4%) |
| Cohort 3f: VIR-2218 200 mg Q4W x ≤13 + PEG-IFNα 180 µg QW x ≤ 44 on NRTI | 0/13 (0.0%) | 1/13 (7.7%) | 13/13 (100.0%) |
Serious adverse events by term
| Term | Organ system | Cohort 1d: VIR-2218 200 mg Q4W x 6 on NRTI | Cohort 2d: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 12 Starting at Week 12 on NRTI | Cohort 3d: VIR-2218 200 mg Q4W x 3 + PEG-IFNα 180 µg QW x 12 on NRTI | Cohort 1f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 24 on NRTI | Cohort 2f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x ≤ 48 on NRTI | Cohort 3f: VIR-2218 200 mg Q4W x ≤13 + PEG-IFNα 180 µg QW x ≤ 44 on NRTI |
|---|
| Biliary colic | Hepatobiliary disorders | 0/15 | 0/15 | 0/5 | 0/18 | 0/18 | 1/13 |
| Ankle fracture | Injury, poisoning and procedural complications | 0/15 | 0/15 | 0/5 | 1/18 | 0/18 | 0/13 |
| Mania | Psychiatric disorders | 0/15 | 0/15 | 0/5 | 0/18 | 1/18 | 0/13 |
Other adverse events by term
| Term | Organ system | Cohort 1d: VIR-2218 200 mg Q4W x 6 on NRTI | Cohort 2d: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 12 Starting at Week 12 on NRTI | Cohort 3d: VIR-2218 200 mg Q4W x 3 + PEG-IFNα 180 µg QW x 12 on NRTI | Cohort 1f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 24 on NRTI | Cohort 2f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x ≤ 48 on NRTI | Cohort 3f: VIR-2218 200 mg Q4W x ≤13 + PEG-IFNα 180 µg QW x ≤ 44 on NRTI |
|---|
| Myalgia | Musculoskeletal and connective tissue disorders | 1/15 | 1/15 | 1/5 | 6/18 | 3/18 | 4/13 |
| Headache | Nervous system disorders | 1/15 | 3/15 | 0/5 | 4/18 | 3/18 | 4/13 |
| Injection site erythema | Immune system disorders | 1/15 | 2/15 | 1/5 | 2/18 | 5/18 | 2/13 |
| Pyrexia | General disorders | 0/15 | 3/15 | 0/5 | 3/18 | 5/18 | 2/13 |
| Fatigue | General disorders | 0/15 | 5/15 | 1/5 | 2/18 | 2/18 | 1/13 |
| Neutrophil count decreased | Investigations | 0/15 | 1/15 | 1/5 | 1/18 | 4/18 | 4/13 |
| Influenza like illness | General disorders | 0/15 | 2/15 | 0/5 | 2/18 | 2/18 | 4/13 |
| COVID-19 | Infections and infestations | 0/15 | 0/15 | 0/5 | 0/18 | 2/18 | 6/13 |
| Back pain | Musculoskeletal and connective tissue disorders | 3/15 | 1/15 | 0/5 | 0/18 | 0/18 | 3/13 |
| Diarrhoea | Gastrointestinal disorders | 1/15 | 2/15 | 0/5 | 0/18 | 3/18 | 1/13 |
| Dyspepsia | Gastrointestinal disorders | 1/15 | 2/15 | 0/5 | 1/18 | 0/18 | 2/13 |
| Injection site pruritus | Skin and subcutaneous tissue disorders | 1/15 | 1/15 | 0/5 | 2/18 | 0/18 | 2/13 |
| Vaccination site pain | General disorders | 1/15 | 1/15 | 0/5 | 1/18 | 2/18 | 1/13 |
| Injection site bruising | General disorders | 0/15 | 1/15 | 0/5 | 2/18 | 2/18 | 0/13 |
| Pruritus | Skin and subcutaneous tissue disorders | 0/15 | 1/15 | 0/5 | 0/18 | 2/18 | 2/13 |
| Rash | Skin and subcutaneous tissue disorders | 0/15 | 2/15 | 0/5 | 2/18 | 0/18 | 1/13 |
| Decreased appetite | Metabolism and nutrition disorders | 0/15 | 1/15 | 0/5 | 0/18 | 3/18 | 0/13 |
| Erythema | General disorders | 0/15 | 1/15 | 0/5 | 0/18 | 1/18 | 2/13 |
| Injection site pain | General disorders | 1/15 | 0/15 | 0/5 | 0/18 | 2/18 | 1/13 |
| Injection site rash | General disorders | 0/15 | 1/15 | 0/5 | 1/18 | 1/18 | 1/13 |
| Alanine aminotransferase increased | Investigations | 0/15 | 1/15 | 0/5 | 2/18 | 0/18 | 0/13 |
| Arthralgia | Musculoskeletal and connective tissue disorders | 2/15 | 0/15 | 1/5 | 0/18 | 0/18 | 0/13 |
| Cough | Respiratory, thoracic and mediastinal disorders | 0/15 | 0/15 | 0/5 | 1/18 | 1/18 | 1/13 |
| Depressed mood | Psychiatric disorders | 0/15 | 1/15 | 0/5 | 0/18 | 1/18 | 1/13 |
| Malaise | General disorders | 0/15 | 0/15 | 0/5 | 1/18 | 1/18 | 1/13 |
| Nausea | Gastrointestinal disorders | 0/15 | 2/15 | 0/5 | 0/18 | 0/18 | 1/13 |
| Stomatitis | Gastrointestinal disorders | 1/15 | 1/15 | 0/5 | 1/18 | 0/18 | 0/13 |
| Upper respiratory tract infection | Infections and infestations | 0/15 | 1/15 | 0/5 | 0/18 | 2/18 | 0/13 |
| White blood cell count decreased | Investigations | 0/15 | 0/15 | 1/5 | 1/18 | 0/18 | 1/13 |
| Abdominal distension | Gastrointestinal disorders | 0/15 | 1/15 | 0/5 | 0/18 | 1/18 | 0/13 |
| Aspartate aminotransferase increased | Investigations | 0/15 | 1/15 | 0/5 | 1/18 | 0/18 | 0/13 |
| Dizziness | Nervous system disorders | 0/15 | 1/15 | 0/5 | 0/18 | 0/18 | 1/13 |
| Gastritis | Gastrointestinal disorders | 1/15 | 0/15 | 0/5 | 0/18 | 0/18 | 1/13 |
| Insomnia | Psychiatric disorders | 0/15 | 0/15 | 0/5 | 0/18 | 1/18 | 1/13 |
| Leukopenia | Blood and lymphatic system disorders | 0/15 | 0/15 | 0/5 | 0/18 | 1/18 | 1/13 |
| Ligament sprain | Injury, poisoning and procedural complications | 0/15 | 1/15 | 0/5 | 0/18 | 0/18 | 1/13 |
| Mouth ulceration | Gastrointestinal disorders | 0/15 | 2/15 | 0/5 | 0/18 | 0/18 | 0/13 |
| Non-cardiac chest pain | General disorders | 1/15 | 0/15 | 0/5 | 0/18 | 0/18 | 1/13 |
| Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | 0/15 | 0/15 | 0/5 | 0/18 | 1/18 | 1/13 |
| Rash pruritic | General disorders | 0/15 | 0/15 | 0/5 | 1/18 | 0/18 | 1/13 |
| Retinopathy | Eye disorders | 0/15 | 0/15 | 0/5 | 1/18 | 0/18 | 1/13 |
| Seborrhoeic dermatitis | General disorders | 1/15 | 0/15 | 0/5 | 0/18 | 1/18 | 0/13 |
| Visual impairment | Eye disorders | 0/15 | 0/15 | 0/5 | 2/18 | 0/18 | 0/13 |
| Weight decreased | Investigations | 0/15 | 1/15 | 0/5 | 0/18 | 0/18 | 1/13 |
| Abdominal pain | Gastrointestinal disorders | 0/15 | 1/15 | 0/5 | 0/18 | 0/18 | 0/13 |
| Abdominal pain upper | Gastrointestinal disorders | 0/15 | 0/15 | 0/5 | 0/18 | 0/18 | 1/13 |
| Abscess limb | Infections and infestations | 0/15 | 1/15 | 0/5 | 0/18 | 0/18 | 0/13 |
| Alopecia | Skin and subcutaneous tissue disorders | 0/15 | 0/15 | 0/5 | 0/18 | 0/18 | 1/13 |
| Ankle fracture | Injury, poisoning and procedural complications | 0/15 | 0/15 | 0/5 | 1/18 | 0/18 | 0/13 |
| Aphthous ulcer | Gastrointestinal disorders | 0/15 | 0/15 | 0/5 | 1/18 | 0/18 | 0/13 |
| Arthropod bite | Injury, poisoning and procedural complications | 0/15 | 0/15 | 1/5 | 0/18 | 0/18 | 0/13 |
| Asthenia | General disorders | 0/15 | 0/15 | 0/5 | 0/18 | 1/18 | 0/13 |
| Biliary colic | Hepatobiliary disorders | 0/15 | 0/15 | 0/5 | 0/18 | 0/18 | 1/13 |
| Cellulitis | Infections and infestations | 0/15 | 0/15 | 1/5 | 0/18 | 0/18 | 0/13 |
| Chalazion | Eye disorders | 0/15 | 0/15 | 0/5 | 0/18 | 0/18 | 1/13 |
| Chest discomfort | General disorders | 0/15 | 0/15 | 0/5 | 0/18 | 0/18 | 1/13 |
| Chest pain | General disorders | 1/15 | 0/15 | 0/5 | 0/18 | 0/18 | 0/13 |
| Conjunctivitis | Infections and infestations | 0/15 | 0/15 | 0/5 | 0/18 | 0/18 | 1/13 |
| Constipation | Gastrointestinal disorders | 0/15 | 0/15 | 0/5 | 0/18 | 1/18 | 0/13 |
| Costochondritis | Musculoskeletal and connective tissue disorders | 0/15 | 0/15 | 0/5 | 1/18 | 0/18 | 0/13 |
48 more terms not shown.
+Locations (22)
| Facility | City | Country | Status |
|---|
| Investigative Site | Birtinya, Queensland | Australia | |
| Investigative Site | Fitzroy, Victoria | Australia | |
| Investigative site | Hong Kong | Hong Kong | |
| Investigative Site | Batu Caves | Malaysia | |
| Investigative Site | Kajang | Malaysia | |
| Investigative Site | Kuala Lumpur | Malaysia | |
| Investigative Site | Kuantan | Malaysia | |
| Investigative Site | Auckland | New Zealand | |
| Investigative Site | Auckland | New Zealand | |
| Investigative Site | Busan | South Korea | |
| Investigative Site | Chuncheon | South Korea | |
| Investigative Site | Daegu | South Korea | |
| Investigative Site | Seoul | South Korea | |
| Investigative Site | Seoul | South Korea | |
| Investigative Site | Yangsan | South Korea | |
| Investigative Site | Bangkok | Thailand | |
| Investigative Site | Bangkok | Thailand | |
| Investigative Site | Bangkok | Thailand | |
| Investigative Site | Chiang Mai | Thailand | |
| Investigative Site | Hat Yai | Thailand | |
| Investigative Site | Khlong Luang | Thailand | |
| Investigative Site | Khon Kaen | Thailand | |
+Study documents